Repeat Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors: A NET Center of Excellence Experience.
Udhayvir S GrewalBradley T LoefflerAlexander PaschkeJoseph S DillonChandrikha Chandrasekharan
Published in: Journal of gastrointestinal cancer (2024)
We show that repeat PRRT may benefit select patients and have an acceptable safety profile. In our cohort, PFS was significantly lower after PRRT2 as compared to PRRT1.